RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:284395

Well-differentiated fetal adenocarcinoma of the lung

medium confidenceDisorder

Also known as: WDFA

Publications

360

80.2th percentile

Trials

0

Interventional, condition-specific

Researchers

1,216

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Well-differentiated fetal adenocarcinoma of the lung is a rare, primary, low-grade, bronchopulmonary neoplasm characterized by a well-circumscribed, usually large, pulmonary mass that is histologically composed of glycogen-rich neoplastic glands and tubules that resemble fetal lungs at 10 to 16 weeks of gestation and benign adjacent stroma. It typically presents with chest pain, cough, dyspnea, hemoptysis and/or generalized, non-specific symptoms, such as night sweats, lethargy, poor appetite and weight loss.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (10)

fetal adenocarcinoma · fetal lung adenocarcinoma · foetal adenocarcinoma · foetal lung adenocarcinoma · pulmonary adenocarcinoma of fetal type · pulmonary adenocarcinoma of foetal type · pulmonary endodermal tumor resembling fetal lung · pulmonary endodermal tumour resembling foetal lung · well-differentiated fetal lung adenocarcinoma · well-differentiated foetal lung adenocarcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    360 matched papers (220 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 3692 for broader category adenocarcinoma

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

360

360 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

360 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

220 in the last 10 years · medium confidence · 80.2th percentile (publications denominator)

Phrase hits: 360 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,216

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Li Y6 papers · 2026

    Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

    Papers in Europe PMC
  2. 02
    Dehner LP5 papers · 2026

    Department of Pathology and Immunology, Lauren V. Ackerman Laboratory of Surgical Pathology, Washington University School of Medicine, St. Louis, Missouri.

    Papers in Europe PMC
  3. 03
    Foulkes WD5 papers · 2025

    Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada; Department of Medical Genetics, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada. Electronic address: william.foulkes@mcgill.ca.

    Papers in Europe PMC
  4. 04
    Han Y5 papers · 2024

    Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, 241 Huaihai West Road, Xuhui District, Shanghai, 200030, China. ychan@cmu.edu.cn.

    Papers in Europe PMC
  5. 05
    Li H5 papers · 2026

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

    Papers in Europe PMC
  6. 06
    Li X5 papers · 2024

    Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.

    Papers in Europe PMC
  7. 07
    Wang Z5 papers · 2022

    Department of Thoracic Surgery Shandong Provincial Hospital affiliated to Shandong University Jinan Shandong China.

    Papers in Europe PMC
  8. 08
    Zhao J5 papers · 2024

    Department of Pathology, The First Affiliated Hospital of Medical College, Zhejiang University Hangzhou, China.

    Papers in Europe PMC
  9. 09
    Gao Y4 papers · 2025

    Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

    Papers in Europe PMC
  10. 10
    Hill DA4 papers · 2026

    ResourcePath LLC, Sterling, Virginia.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 3,692 trials are registered for adenocarcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

3,692 interventional trials matched adenocarcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: adenocarcinoma

3,692

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Well-differentiated fetal adenocarcinoma of the lung" OR "Well-differentiated fetal adenocarcinoma of lung" OR "fetal adenocarcinoma" OR "fetal lung adenocarcinoma" OR "foetal adenocarcinoma" OR "foetal lung adenocarcinoma" OR "pulmonary adenocarcinoma of fetal type" OR "pulmonary adenocarcinoma of the fetal type" OR "pulmonary adenocarcinoma of foetal type" OR "pulmonary adenocarcinoma of the foetal type" OR "pulmonary endodermal tumor resembling fetal lung" OR "pulmonary endodermal tumour resembling foetal lung" OR "well-differentiated fetal lung adenocarcinoma" OR "well-differentiated foetal lung adenocarcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Well-differentiated fetal adenocarcinoma of the lung" OR "Well-differentiated fetal adenocarcinoma of lung" OR "fetal adenocarcinoma" OR "fetal lung adenocarcinoma" OR "foetal adenocarcinoma" OR "foetal lung adenocarcinoma" OR "pulmonary adenocarcinoma of fetal type" OR "pulmonary adenocarcinoma of the fetal type" OR "pulmonary adenocarcinoma of foetal type" OR "pulmonary adenocarcinoma of the foetal type" OR "pulmonary endodermal tumor resembling fetal lung" OR "pulmonary endodermal tumour resembling foetal lung" OR "well-differentiated fetal lung adenocarcinoma" OR "well-differentiated foetal lung adenocarcinoma"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"adenocarcinoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: WDFA

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T12:04:14.555Z